A STUDY OF SPECSIN IN OBESE CHILDREN ON THE BACKGROUND OF THERAPY WITH A GLUCAGON-LIKE PEPTIDE-1 ANALOG

Relevance. Recently, the incidence of obesity among the child population has been steadily increasing. Adipokine hormones, which affect the level of metabolic processes, play a significant role in the development of this pathology. One of these substances is spexin, which is currently being considered as a possible marker of cardiometabolic risk in obese patients. Goal. To study the level of specsin in obese children using a glucagon-like peptide-1 receptor agonist liraglutide. Materials and methods. A study of the level of spexin was conducted in obese children before the start of therapy and 3 months after the use of liraglutide. The level of spexin was determined by enzyme immunoassay using a set of Spexin/Neuropeptide Q reagents. The results obtained and their discussion. The study included 23 patients with an established diagnosis of constitutionally exogenous obesity of II-III degrees and morbid obesity, and a group of patients with 20 children over 12 years of age with a normal BMI was taken for comparison.As a result of our study, it was revealed that the level of spexin in obese children was higher than in healthy children, but at the same time it was within the reference values. According to the results of our studies, when repeated treatment 3 months after the start of liraglutide therapy, there are significant differences in the level of spexin not identified.However, significant changes in body weight were noted in the study group (before the start of therapy, the average value was 98 kg, after 3 months this indicator was 90 kg). Conclusion. No data were found on the effect on the level of spexin in children during complex therapy using a glucagon-like peptide-1 receptor agonist liraglutide. At the same time, a positive effect of therapy was observed, which manifested itself in a decrease in body weight in the study group of patients.